Effect of nitazoxanide in diarrhea and enteritis caused by Cryptosporidium species.
OBJECTIVE
The aim of this study was to evaluate the efficacy of nitazoxanide for the treatment of diarrhea and enteritis caused by Cryptosporidium species in patients 12 years of age and older.


METHODS
A multicenter, randomized, double-blind, placebo-controlled study was conducted in 90 outpatients 12 years of age and older from the Nile Delta region of Egypt. Patients were randomized to receive either one 500 mg tablet or one matching placebo tablet, or 25 mL of nitazoxanide oral suspension (500 mg nitazoxanide), each given twice daily for 3 days. Clinical and microbiologic response rates were evaluated 4 days after completion of treatment.


RESULTS
Twenty-seven (96%) of the 28 patients receiving nitazoxanide tablets responded clinically compared with 11 (41%) of 27 patients who received placebo (P < .0001). Twenty-six (93%) of the 28 patients who received nitazoxanide were free of Cryptosporidium oocysts in each of 2 posttreatment stool samples compared with only 10 (37%) of 27 patients who received placebo (P < .0001). Response rates in patients receiving the tablets and the suspension were comparable (clinical response rate for suspension, 27 of 31 [87%]; microbiologic response rate for suspension, 28 of 31 [90%]).


CONCLUSIONS
These findings show that a 3-day course of nitazoxanide is effective in treating diarrhea and enteritis caused by Cryptosporidium in nonimmunodeficient patients 12 years of age and older.
Rossignol
Jean-François
JF
The Romark Institute for Medical Research, Tampa, Florida 33607, USA. jrossignol@romark.com
Kabil
Samir M
SM
el-Gohary
Yehia
Y
Younis
Azza M
AM
D000284:Administration, Oral; D000328:Adult; D000977:Antiparasitic Agents / Q000008:administration & dosage*; D003457:Cryptosporidiosis / Q000175:diagnosis / Q000188:drug therapy*; D003967:Diarrhea / Q000188:drug therapy* / Q000382:microbiology; D004311:Double-Blind Method; D004751:Enteritis / Q000188:drug therapy* / Q000382:microbiology; D006801:Humans; D009574:Nitro Compounds; D011446:Prospective Studies; D013535:Suspensions; D013607:Tablets; D013844:Thiazoles / Q000008:administration & dosage*; D016896:Treatment Outcome
D000977:Antiparasitic Agents; D009574:Nitro Compounds; D013535:Suspensions; D013607:Tablets; D013844:Thiazoles; C041747:nitazoxanide